Alzheimer's Breakthrough Drugs Questioned

The analysis found that while the drugs may slow cognitive decline on paper, the clinical difference is often unnoticeable to families and caregivers.

Furthermore, the review highlighted increased risks of brain swelling and bleeding associated with the treatments.

The findings have provoked a vicious backlash from some scientists who label the report as fundamentally flawed.

Despite the controversy, the report urges a shift in focus toward more effective therapeutics and better long-term care for those living with the disease.